- Home
- SYRE vs ORKA Comparison
SYRE vs ORKA Comparison
Compare SYRE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- ORKA
- Stock Information
- Founded
- SYRE 2013
- ORKA 2004
- Country
- SYRE United States
- ORKA United States
- Employees
- SYRE N/A
- ORKA N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SYRE Health Care
- ORKA Health Care
- Exchange
- SYRE Nasdaq
- ORKA Nasdaq
- Market Cap
- SYRE 1.1B
- ORKA 1.2B
- IPO Year
- SYRE 2016
- ORKA N/A
- Fundamental
- Price
- SYRE $23.71
- ORKA $27.20
- Analyst Decision
- SYRE Strong Buy
- ORKA Strong Buy
- Analyst Count
- SYRE 5
- ORKA 9
- Target Price
- SYRE $55.75
- ORKA $45.22
- AVG Volume (30 Days)
- SYRE 741.8K
- ORKA 388.3K
- Earning Date
- SYRE 11-04-2025
- ORKA 11-12-2025
- Dividend Yield
- SYRE N/A
- ORKA N/A
- EPS Growth
- SYRE N/A
- ORKA N/A
- EPS
- SYRE N/A
- ORKA N/A
- Revenue
- SYRE N/A
- ORKA N/A
- Revenue This Year
- SYRE N/A
- ORKA N/A
- Revenue Next Year
- SYRE N/A
- ORKA N/A
- P/E Ratio
- SYRE N/A
- ORKA N/A
- Revenue Growth
- SYRE N/A
- ORKA N/A
- 52 Week Low
- SYRE $10.91
- ORKA $5.49
- 52 Week High
- SYRE $33.47
- ORKA $29.98
- Technical
- Relative Strength Index (RSI)
- SYRE 60.31
- ORKA 56.20
- Support Level
- SYRE $21.63
- ORKA $25.57
- Resistance Level
- SYRE $24.19
- ORKA $29.98
- Average True Range (ATR)
- SYRE 1.33
- ORKA 2.19
- MACD
- SYRE -0.26
- ORKA -0.43
- Stochastic Oscillator
- SYRE 67.01
- ORKA 36.81
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.